Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.
Info

Questions:

  1. Is screening considered visit 1, or is it to include the subject into the study? SDTM team agreed to change to VISIT 1 instead of SCREENING.
  2. Are these Real World Evidence (RWE) studies only or clinical trials?
  3. Should both endpoints be shown in one efficacy dataset or two? I will be showing 3 datasets.
  4. What is a good surface area to use for the child subject?
  5. Should i use Male and 6 years? please advise.

This example illustrates In this section, example analysis datasets are shown for the following endpoints:

  • From CV domain
    • Percent change in ejection fraction over time
    • Decline in ejection fraction over a time period (yearly) grouped by a decline greater than 10.0%.
  • From the LB domain
    • Percent change in NTproBNP over a period of time (yearly).

Source Data

The SDTM examples used as the source data are from Section 2.1, Basic CMR Tests - Systolic Function. The CV dataset contains 16 rows, 1-8 for visit 1 and 9-16 for visit 6. Of these rows, the ones where CVTESTCD = "LVEF_C" and CVTESTCD =  "RVEF_C" representing the Ventricular Ejection Fraction, Calculated (%) for left and right were selected for the analysis. The LB dataset test were used for analysis. In the LB dataset, the records where LBTESTCD = "BNPPRONT" was were used to add the value of BNPPRONT to compute the percent percentage change over time, and then it was added as a ptential potential covariate in each row for the last analysis.   As in all ADaM datasets, the The SDTM datasets were merged with a Subject Level Analysis Dataset (ADSL) was merged in dataset to record the SDTM datasets to capture all the necessary demographics, treatments and other required appropriate variables for analysis of the data.

...

ADaM Datasets

The example analysis dataset includes treatment and demographic information drawn from the ADSL, defined in the Metadata Table metadata table below. In this example, only some of the required variables, plus important stratification variables from ADSL, are shown for illustrative purposes. For example, one variable added; body surface area at baseline (BSABL)   was computed for baseline records in ADSL. However, since the subjects are children, the body surface area changes over time. Therefore, it would probably be necessary to have a separate dataset to represent this over time.

The table below shows the example analysis datasets and unique parameters for this exampleendpoint. The Subject Level Analysis Dataset (ADSL)   is a necessary component in the creation process of subsequent analysis datasets for human trials. The ADSL incorporates demographics, treatment groups, study dates, and stratification variables. In this example, the ADSL is not illustrated, but serves as a source for standard ADaM variables. Additional information can be found in Section 2.3.1 of the ADaM Implementation Guide (ADaMIG) v1.3.

...

Definexmltable
Multipletrue
LevelDataset
PurposeAnalysis

Dataset Name

Dataset Description

Class of Dataset

Structure

Location

Keys

Documentation

ADSL

Subject-Level Analysis Dataset

SUBJECT LEVEL ANALYSIS DATASETadsl.xptOne record per subjectUSUBJIDADaMIG v1.3 section 3.1.1
ADCVNTPCardiac Ejection Fraction and NTproBNP Analysis Dataset

BASIC DATA STRUCTURE

One record per subject per analysis visit per parameter.adcvntrp.xptUSUBJID, AVISITN, PARAMN

Analysis Dataset


ADSL Analysis Dataset


ADCVNTP Analysis Dataset

Definexmltable
DatasetADCVNTP
LevelValue
PurposeAnalysis
OIDAVAL
DatasetVariableWhereTypeOriginDerivation/Comment
ADCVNTPAVALPARAMCD = "LVEFC"NumPredecessorSet to CV.CVSTRESN where CV.CVTESTCD = "LVEF_C"
ADCVNTPAVALPARAMCD = "RVEFC"NumPredecessorSet to CV.CVSTRESN where CV.CVTESTCD = "RVEF_C"
ADCVNTPAVALPARAMCD = "BNPPRONT"NumPredecessorSet to LB.LBSTRESN where LB.LBTESTCD = "BNPPRONT"

...

The subsequent section provides the data structures for the example ADaM datasets. In this example, columns for derived variables BASE, CHG, PCHG and CHGCAT1 have been added to facilitate analyses of the efficacy endpoints. Specifically, example demographic data for ADSL were created for an 8 year old male. Also, a custom variable for BSA at baseline (BSABASE), was added from ADSL.

Definexmltable
DatasetADCVNTP
LevelVariable
PurposeAnalysis
NameVariable
Variable NameVariable LabelTypeCodelist/Controlled Terms/FormatSourceDerivation/Comment
STUDYIDStudy IdentifierChar

CV.STUDYID


USUBJIDUnique Subject IdentifierChar

CV.USUBJID

Select for records with RE data.
ASEQAnalysis Sequence NumberNum

CV.CVSEQ

Number records 1 to n after sorting by keys.
BSABASEBody Surface Area (m2) at BaselineNum
ADSL.BSABASECompute in ADSL where VS.VSTESTCD = "BSA".
PARAMParameterChar

Left Ventricular Ejection Fraction, Calculated (%);

Right Ventricular Ejection Fraction, Calculated (%);

N-Terminal ProB-type Natriuretic Peptide (pg/mL)


For tests from CV, set to the values of CV.CVTEST plus CV.CVTESTU with spaces and parentheses as shown. 

For tests from LB, set to the value of LB.LBTEST plus LB.LBTESTU with spaces and parentheses as shown. 

PARAMCDParameter CodeChar

LVEFC;

RVEFC;

BNPPRONT;




If CV.CVTESTCD = "LVEF_C" then PARAMCD = "LVEFC"

If CV.CVTESTCD = "RVEF_C" then PARAMCD = "RVEFC".

If LB.LBTESTDC = "BNPPRONT" then PARAMCD = "BNPPRONT.

Note: for this example dataset, select the records where the test values shown above are included.

PARAMNParameter (N)Num



Number PARAMCD as follows:

LVEFC = "1"

RVEFC = "2"

BNPPRONT = "3"

AVALAnalysis ValueNum


See Parameter Value List 

AVISITAnalysis VisitChar



If CV.VISIT = "VISIT 1" then AVISIT = "Visit 1 (Baseline)".

Else if CV.VISIT = "VISIT 6" then AVISIT = "Visit 6 (1 Year)".

AVISITNAnalysis Visit (N)Num

Set to value of CV.VISITNUM or LB.VISITNUM
VISITVisitNum

CV.VISIT

LB.VISIT


ADTAnalysis DateNumdate9.
Date portion of CV.CVDTC or LB.LBDTC converted to numeric and displayed in a format such as date9. 
ABLFLBaseline Record FlagCharY

If CV.VISIT = 1 then ABLFL = "Y".

BASEBaseline ValueNum

Set BASE to AVAL from the record for that subject and parameter where ABLFL = "Y".

Populate BASE for additional visits by copying the value of BASE in the baseline record by USUBJID and ADT. (Or by AVISIT if ADT varies for labs, where windowing is applied to select record closest to the visit)

CHGChange from BaselineNum

Compute CHG = AVAL - BASE for that record. Only compute for post-baseline records.
PCHGPercent Change from BaselineNum

Compute PCHG = (CHG / BASE) * 100. Only compute for post-baseline records.
CHGCAT1Change from Baseline Category 1Char

Decline >=10.0;

Decline < 10.0; 

Increase


Categorize the value of CHG for Left Ventricular Ejection Fraction, and Calculated (%) (LVEFC) and for Right Ventricular Ejection Fraction, Calculated (%) (RVEFC)
CHGCAT2Change from Baseline Category 2Chart



Categorize the value of CHG for N-Terminal ProB-type Natriuretic Peptide (pg/mL) (BNPPRONT)
TRT01P

Planned Treatment for Period 01

CharTreatment AADSL.TRT01PFor this example we are using "Treatment A". In a Real World Evidence study this could be non-treatment related, e.g. "Group A".

ITTFL

Intent-To-Treat Population Flag

Char

Y; N

ADSL.ITTFL


AGEAgeNum
ADSL.AGE
AGEUAge UnitsChar(AGEU)ADSL.AGEU
SEXSexChar(SEX)ADSL.SEX
SRCDOMSource DataChar

CV; LB


Set to the SDTM domain name that relates to the analysis value.
SRCSEQSource Sequence NumberNum


CV.CVSEQ

LB.LBSEQ

Set to the SDTM domain sequence number that relates to the analysis value.

Example 1

This example dataset shows the findings and additional analysis variables associated with:

...

Dataset wrap
Nameadcvntp
Dataset2
tableidadcvntp
RowSTUDYIDUSUBJIDASEQBSABASEBNPPRONTBNPCHGPARAMPARAMCDPARAMNAVALAVISITAVISITNVISITADTABLFLBASECHGPCHGTRT01PITTFLAGEAGEUSEXSRCDOMSRCSEQ
1DMD-EFLGEDMD-EFLGE-10110.6540
Left Ventricular Ejection Fraction, Calculated (%)LVEFC167Visit 1 (Month 1)1VISIT 116MAY2022Y67

Treatment AY8YEARSMCV3
2DMD-EFLGEDMD-EFLGE-10120.6540
Right Ventricular Ejection Fraction, Calculated (%)RVEFC274Visit 1 (Month 1)1VISIT 116MAY2022Y74

Treatment AY8YEARSMCV7
3DMD-EFLGEDMD-EFLGE-10130.659002150Left Ventricular Ejection Fraction, Calculated (%)LVEFC160Visit 6 (Month 12)6VISIT 601JUN2023
67-7-10.447761Treatment AY8YEARSMCV11
4DMD-EFLGEDMD-EFLGE-10140.659002150Right Ventricular Ejection Fraction, Calculated (%)RVEFC261Visit 6 (Month 12)6VISIT 601JUN2023
74-13-17.567568Treatment AY8YEARSMCV15

Example Analysis Results Metadata (ARM) Tables

This table may be included in the submission package for regulatory agencies. It describes the analyses conducted for the study (usually limited to primary and secondary  endpoints) with details on data and analysis procedures used. The first example uses the dataset ADCVNTPR, selecting for the parameter "N-Terminal ProB-type Natriuretic Peptide (IU/L)"is an example ARM table for the selected endpoint. Other endpoints can be represented in the same way describing the variables and procedures used. For more details on ARM, see the ADaMIG and the ARM implementation in Define-XML (available at https://www.cdisc.org/standards/foundational/define-xml/).

Display

Table 14.xx.xx Percent change in NTproBNP over a period of time (yearly)

Analysis ResultComparison of Percent Change of NTproBNP for the Treatment Groups Over Time (quarterly or yearly)
Analysis Variables(s)PCHG
Analysis ReasonPrimary efficacy endpoint as prespecified in the SAP
Analysis PurposePrimary outcome measure

Data References

(incl. selection criteria)

PARAMCD = "BNPPRONT"

Where ITTFL = "Y"

Documentation

 The mixed model using lsmeans to compare treatment groups

Programming Statements 

(Add programming language statements here: SAS, R, etc.)

PROC MIXED DATA=ADCVNTPR;

WHERE PARAMCD = "BNPPRONT";

CLASS STUYDID TRT01P AVISITN;

MODEL PCHG=AVISITN*TRT01P/Solution;

RANDOM INTERCEPT / SUBJECT=STUYDID TYPE=UN;

LSMEANS TRT01P*AVISITN/ CL PDIFF;

RUN;

Display

Table 14.xx.xx Percent Change in Left Ventricular Ejection Fraction Over Time

Analysis ResultComparison of Percent Change of Ejection Fraction for the Treatment Groups Over Time (quarterly or yearly)
Analysis Variables(s)PCHG
Analysis ReasonPrimary efficacy endpoint as prespecified in the SAP
Analysis PurposePrimary outcome measure

Data References

(incl. selection criteria)

PARAMCD = "LVEFC"

Where ITTFL = "Y"

Documentation

 The mixed model using lsmeans to compare treatment groups

Programming Statements 

(Add programming language statements here: SAS, R, etc.)

PROC MIXED DATA=ADCVNTP;

CLASS STUYDID TRT01P AVISITN;

MODEL PCHG=AVISITN*TRT01P/Solution;

RANDOM INTERCEPT / SUBJECT=STUYDID TYPE=UN;

LSMEANS TRT01P*AVISITN/ CL PDIFF;

RUN;

...

Ejection Fraction

  • change in ejection fraction, would expect a decline in EF 2-3% per year, would prefer an improvement or no change. Concerning if rapid progression, 10% decline or more, for example.

NTproBNP

  • % change over a period of time – a decrease would mean improvement, annually is appropriate

...

Pagenav2